Related Experiment Video

Updated: Feb 1, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.3K

Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

Kim A Connelly1, Deepak L Bhatt2, Subodh Verma3

  • 1Division of Cardiology, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Cell Metabolism
|December 6, 2018
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors show promise in preventing heart failure and kidney disease in type 2 diabetes patients. The DECLARE-TIMI 58 trial suggests these drugs may offer primary cardio-renal protection.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Type 2 diabetes (T2D) is associated with high risks of heart failure and renal disease.
  • Cardio-renal complications significantly impact morbidity and mortality in T2D patients.

Purpose of the Study:

  • To evaluate the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the primary prevention of cardio-renal events in individuals with T2D.
  • To analyze findings from recent outcome studies, including DECLARE-TIMI 58, regarding SGLT2 inhibitors' cardio-renal protective effects.

Main Methods:

  • Review of recent large-scale outcome trials investigating SGLT2 inhibitors in T2D.
  • Analysis of data from the DECLARE-TIMI 58 trial (Wiviott et al., 2018).

Main Results:

  • Recent studies, including DECLARE-TIMI 58, provide evidence for the cardio-renal benefits of SGLT2 inhibitors.
  • These agents appear to play a role in the primary prevention of cardiovascular and renal complications in T2D.

Conclusions:

  • SGLT2 inhibitors represent a therapeutic class with significant potential for cardio-renal risk reduction in type 2 diabetes.
  • Further research and clinical application of SGLT2 inhibitors are warranted for primary prevention strategies in T2D.

More Related Videos

Direct Drug Delivery to Kidney via the Renal Artery11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.2K
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

3.0K

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.6K
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
223
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
463
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
7.4K
Renal Clearance01:23

Renal Clearance

The glomerular filtration rate (GFR) is a critical marker of kidney function, reflecting the efficiency of filtration by the glomeruli. Renal clearance of specific substances, such as inulin or creatinine, is commonly used to measure GFR.
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
2.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K